AB-CHMINACA

Synthetic cannabinoid

AB-CHMINACA
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number	1185887-21-1
PubChem	71782280
DrugBank
ChemSpider	29342082
KEGG

AB-CHMINACA is a synthetic cannabinoid that has been used as a designer drug. It is a potent agonist of the cannabinoid receptors and has been associated with numerous adverse effects in users.

Chemical structure and properties

AB-CHMINACA is classified as an indazole-based synthetic cannabinoid. Its chemical structure includes a cyclohexylmethyl group attached to the indazole core, with an amide linkage to a 2-methylpropyl group. The IUPAC name for AB-CHMINACA is N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide.

Pharmacology

AB-CHMINACA acts as a potent agonist at the CB1 and CB2 cannabinoid receptors. These receptors are part of the endocannabinoid system, which plays a role in regulating various physiological processes including mood, memory, and pain sensation. The activation of these receptors by AB-CHMINACA can lead to psychoactive effects similar to those of tetrahydrocannabinol (THC), the active component of cannabis.

Adverse effects

The use of AB-CHMINACA has been associated with a range of adverse effects. These can include tachycardia, hypertension, nausea, vomiting, agitation, hallucinations, and seizures. In some cases, severe toxicity and fatalities have been reported. The variability in effects is partly due to differences in individual metabolism and the presence of other substances.

Legal status

Due to its potential for abuse and adverse health effects, AB-CHMINACA has been classified as a controlled substance in many jurisdictions. It is often included in legislation targeting synthetic cannabinoids and other novel psychoactive substances.

Synthesis

The synthesis of AB-CHMINACA involves the reaction of an indazole derivative with a cyclohexylmethyl halide, followed by the introduction of the amide group. The process requires careful control of reaction conditions to ensure the desired product is obtained.

Related pages

• Synthetic cannabinoids
• Cannabinoid receptor
• Designer drug
• Endocannabinoid system

Gallery

• 
  Chemical structure of AB-CHMINACA